Protalix BioTherapeutics at the Investor Forum
Protalix BioTherapeutics, Inc. (NYSE American: PLX) is a prominent biopharmaceutical company known for its unique approach to creating therapeutic proteins. The company specializes in recombinant proteins made using its ProCellEx plant cell-based expression system, demonstrating a strong commitment to advancing healthcare solutions. This September, Protalix plans to take part in an important investor forum, offering them a chance to share their developments directly with the investment community.
Event Details
The presentation will be led by Dror Bashan, Protalix's President and CEO, at the upcoming Life Sciences Investor Forum. This engaging online event is live, allowing attendees to ask questions in real-time. Scheduled for September 19 at 12:00 p.m. Eastern Daylight Time (EDT), the event will also have an archived webcast available for those unable to participate live.
This interactive platform fosters direct engagement between investors and company representatives, promoting transparency and open communication. Protalix encourages interested individuals to pre-register and explore their online systems to enhance their participation experience during the event.
Innovations from Protalix BioTherapeutics
Protalix's dedication to developing innovative therapies has established them as a leader in the biopharmaceutical field. They were the first company to achieve U.S. Food and Drug Administration (FDA) approval for a protein produced through a plant cell-based system, highlighting their forward-thinking methods in recombinant protein production.
Key Products and Partnerships
A flagship product for Protalix is taliglucerase alfa, initially developed to treat Gaucher disease. This treatment has significantly evolved through a collaborative development with Pfizer Inc., which has the global rights for its commercialization, except in Brazil, where Protalix retains full control. Recently, in May 2023, their latest innovation, Elfabrio, received FDA and European Medicines Agency approval, marking a key achievement for the company.
Additionally, Protalix has partnered with Chiesi Farmaceutici S.p.A. to globally commercialize Elfabrio. With a diverse product pipeline, Protalix is actively pursuing several projects, including PRX-115, a recombinant PEGylated uricase for uncontrolled gout, and PRX-119, which targets NETs-related diseases.
Virtual Investor Conferences Overview
Virtual Investor Conferences (VIC) are essential for linking publicly traded companies with a worldwide network of investors. They offer an interactive setting for presentations and discussions, replicating the traditional investor conference experience while improving accessibility through online platforms.
VIC has revolutionized investment communication, allowing companies like Protalix to not only showcase their findings but also to engage in meaningful conversations with investors through targeted one-on-one meetings and real-time questions.
Engaging with Investors
These investor events do more than provide presentations; they offer Protalix the opportunity to broaden their reach and effectively communicate their innovations and progress. In today's climate, where transparency in healthcare is increasingly vital, such engagement plays a crucial role in building investor trust and confidence.
As Protalix BioTherapeutics continues to navigate the biopharmaceutical landscape, they stay committed to improving patient outcomes through novel therapies grounded in strong data and scientific credibility.
Investor Relations Contact
If you have questions regarding Protalix BioTherapeutics or the upcoming investor forum, Mike Moyer, Managing Director at LifeSci Advisors, is available to assist. You can contact him at +1-617-308-4306 or reach him via email.
Frequently Asked Questions
What is Protalix BioTherapeutics known for?
Protalix BioTherapeutics is known for its development of recombinant therapeutic proteins using a plant cell-based expression system.
Who will represent Protalix at the investor forum?
Dror Bashan, the President and CEO of Protalix, will deliver the presentation on behalf of the company.
What is the significance of the investor forum?
The forum allows Protalix to directly engage with investors, showcasing their innovations and addressing questions in real-time.
Where can I find more information about Protalix?
For further details about Protalix’s products and initiatives, you can visit their official website or reach out to their investor relations contact.
How can I participate in the investor forum?
To participate, you can pre-register for the event and prepare for a smooth online experience.
